Long-Term Efficacy of Oral Vancomycin Prophylaxis for the Prevention of Clostridium difficile Recurrence

• Published in: Journal of pharmacy practice Vol. 33; no. 5; p. 633
• Main Authors: Knight, Emmanuel M, Schiller, Daryl S, Fulman, Magda K, Rastogi, Rupangi
• Format: Journal Article
• Language: English
• Published: United States 01.10.2020
• Subjects: Anti-Bacterial Agents - therapeutic use; Clostridioides difficile; Clostridium Infections - drug therapy; Clostridium Infections - epidemiology; Clostridium Infections - prevention & control; Humans; Recurrence; Retrospective Studies; Vancomycin; vancomycin; prophylaxis; recurrent; Clostridium difficile; infectious diseases
• ISSN: 1531-1937
• DOI: 10.1177/0897190019825994

Limited evidence suggests that prophylactic oral vancomycin may be beneficial in preventing infection (CDI) recurrence, but long-term efficacy is unknown. To evaluate the long-term efficacy of oral vancomycin prophylaxis (OVP) in preventing CDI recurrence in subjects who require subsequent antibiotic exposure. A retrospective cohort study was conducted at a community hospital. A total of 91 subjects with a history of CDI between January 2013 and December 2015 who had a subsequent hospitalization requiring systemic antibiotics within 12 months were evaluated. Thirty-two subjects who received prophylaxis with oral vancomycin were compared to 59 subjects who did not receive prophylaxis. CDI recurrence within 12 months was significantly lower in subjects receiving OVP compared to those who did not receive OVP (6.3% vs 28.8%; odds ratio [OR]: 0.16; 95% confidence interval [CI]: 0.04-0.77; .011) including patients whose previous CDI was an initial episode (3.7% [1/27] vs 28.3% [15/53]; OR: 10.3; 95% CI: 1.28-82.6; = .009). Use of OVP in subjects with a history of CDI up to 12 months prior to subsequent antibiotic exposure appears to reduce the risk of CDI recurrence for up to 12 months.